Real-world cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Taiwan

被引：0
|
作者：
Ben Johnson
Edward Chia-Cheng Lai
Huang-tz Ou
Hong Li
Björn Stollenwerk
机构：
[1] Amgen Ltd,Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine
[2] National Cheng Kung University,undefined
[3] Amgen Asia Holding Limited,undefined
[4] Amgen GmbH,undefined
来源：
Archives of Osteoporosis | 2021年 / 16卷
关键词：
Denosumab; Real-world; Cost-effectiveness; Osteoporosis; Postmenopausal; Taiwan;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Real-world cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Taiwan
    Johnson, Ben
    Lai, Edward Chia-Cheng
    Ou, Huang-tz
    Li, Hong
    Stollenwerk, Bjorn
    ARCHIVES OF OSTEOPOROSIS, 2021, 16 (01)
  • [2] Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis
    Jonsson, B.
    Strom, O.
    Eisman, J. A.
    Papaioannou, A.
    Siris, E. S.
    Tosteson, A.
    Kanis, J. A.
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 (03) : 967 - 982
  • [3] Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis
    B. Jönsson
    O. Ström
    J. A. Eisman
    A. Papaioannou
    E. S. Siris
    A. Tosteson
    J. A. Kanis
    Osteoporosis International, 2011, 22 : 967 - 982
  • [4] Comment on: cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis
    B. Jönsson
    O. Ström
    J. A. Eisman
    A. Papaioannou
    E. S. Siris
    A. Tosteson
    J. A. Kanis
    Osteoporosis International, 2012, 23 : 2063 - 2065
  • [5] Cost-effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in Malaysia
    Choo, Y. W.
    Mohd Tahir, N. A.
    Mohamed Said, M. S.
    Li, S. C.
    Makmor Bakry, M.
    OSTEOPOROSIS INTERNATIONAL, 2022, 33 (09) : 1909 - 1923
  • [6] COST-EFFECTIVENESS OF DENOSUMAB IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS IN SCOTLAND
    Davies, A.
    Compston, J.
    Ferguson, S.
    McClosky, E.
    Shearer, A.
    Taylor, A.
    VALUE IN HEALTH, 2011, 14 (07) : A310 - A310
  • [7] Comment on: cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis
    Jonsson, B.
    Stroem, O.
    Eisman, J. A.
    Papaioannou, A.
    Siris, E. S.
    Tosteson, A.
    Kanis, J. A.
    OSTEOPOROSIS INTERNATIONAL, 2012, 23 (07) : 2063 - 2065
  • [8] Cost-effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in Malaysia
    Y. W. Choo
    N. A. Mohd Tahir
    M. S. Mohamed Said
    S. C. Li
    M. Makmor Bakry
    Osteoporosis International, 2022, 33 : 1909 - 1923
  • [9] COST-EFFECTIVENESS COMPARISON OF DENOSUMAB AND ZOLEDRONIC ACID IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
    Ding, Y.
    Hay, J.
    VALUE IN HEALTH, 2014, 17 (03) : A47 - A47
  • [10] Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women
    Hiligsmann, Mickael
    Boonen, Annelies
    Dirksen, Carmen D.
    Ben Sedrine, Wafa
    Reginster, Jean-Yves
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2013, 13 (01) : 19 - 28
12345